Urocortin: natural stress & heart-protection hormone (UCN1)
A natural brain hormone that regulates the stress response, protects the heart, and suppresses appetite; elevated in heart failure; experimental, not yet an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Endogenous peptide — produced naturally and routinely synthesized for research
Fork this card to add platform evidence →
Endogenous peptide — receptor binding and activity established in published literature
Fork this card to add platform evidence →
What this is
Urocortin (UCN1, also called urocortin 1) is a 40-amino acid neuropeptide hormone belonging to the corticotropin-releasing factor (CRF) superfamily. It was isolated from rat midbrain in 1995 by Vaughan and colleagues and named for its sequence homology to fish urotensin I and mammalian CRF (Vaughan et al., Nature 1995). UCN1 is the only member of the CRF family that binds with high affinity to both CRF receptor subtypes — CRF1 (CRHR1) and CRF2 (CRHR2) — distinguishing it from CRF, which preferentially binds CRF1, and from urocortin 2 and urocortin 3, which are CRF2-selective. This dual receptor engagement gives UCN1 a broader physiological profile than either CRF or the other urocortins. The stored sequence DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV is the canonical human UCN1 peptide as isolated and characterized by Vaughan and colleagues; it represents the bare backbone and does not include any post-translational modifications.
UCN1 is expressed predominantly in the Edinger-Westphal nucleus of the midbrain, the hypothalamus, and peripheral tissues including myocardium, the gastrointestinal tract, skin, thymus, testis, and uterus (Bale and Vale 2004). In the brain, UCN1 participates in stress-response coordination, appetite suppression, anxiety-like behavior, and autonomic regulation. In the cardiovascular system, UCN1 exerts protective effects: it is a potent vasodilator, has positive inotropic action at low doses, and protects cardiomyocytes from ischemia-reperfusion injury. Plasma UCN1 is elevated in human heart failure and correlates with disease severity (Wright and colleagues 2009).
UCN1 is not approved as a therapeutic agent. Clinical development within the urocortin family has focused primarily on urocortin 2 (UCN2), the CRF2-selective member, which has been evaluated in early-phase trials for acute decompensated heart failure. UCN1 itself has been studied in human forearm blood flow models and in observational heart failure studies, but no UCN1-based drug has reached late-phase clinical trials.
History
The existence of a CRF-related mammalian peptide distinct from CRF itself was inferred from two observations: (1) the discovery of fish urotensin I — a CRF-like peptide — with potent cardiovascular and behavioral activities; and (2) high-affinity CRF binding in brain regions where CRF expression was undetectable, suggesting an endogenous CRF receptor ligand other than CRF. Vaughan and colleagues at the Salk Institute identified this ligand by fractionating rat midbrain extracts for CRF receptor displacement activity, ultimately isolating the 40-residue peptide they named urocortin (Vaughan et al., Nature 1995).
The original 1995 Nature paper demonstrated that synthetic urocortin bound CRF receptors with affinity equal to or exceeding CRF, stimulated ACTH release from anterior pituitary cells, activated both CRF1 and CRF2 receptors (with higher affinity for CRF2 than CRF exhibits), and was expressed in Edinger-Westphal nucleus neurons projecting to spinal cord and peripheral targets. Intracerebroventricular urocortin reduced food intake and increased anxiety-like behavior in rats, consistent with CRF receptor-mediated stress activation.
Two additional CRF2-selective family members were subsequently identified: urocortin 2 (UCN2, also called stresscopin-related peptide) and urocortin 3 (UCN3, also called stresscopin) — both expressed in distinct hypothalamic and peripheral patterns. The full pharmacology of these three urocortins, their shared and distinct receptor profiles, and their roles in stress responsivity and behavioral regulation are reviewed comprehensively by Bale and Vale (2004).
The cardiovascular biology of UCN1 emerged from observations that CRF2 receptors are expressed at high density in myocardium and that UCN1 exerts strong inotropic and vasodilatory effects in cardiac preparations. Wright and colleagues (Circulation: Heart Failure 2009) demonstrated that plasma UCN1 is significantly elevated in patients with systolic heart failure compared to healthy controls, with UCN1 levels correlating with NYHA functional class, NT-proBNP, and left ventricular ejection fraction. This established UCN1 as a disease-severity biomarker in human heart failure — possibly representing a counter-regulatory adaptive response to cardiac stress, analogous to the natriuretic peptide surge.
What it does
UCN1 binds CRF1 and CRF2 receptors, both class B G-protein-coupled receptors (GPCRs) that couple primarily to Gαs and generate cAMP as the primary second messenger, with secondary activation of MAPK pathways depending on cell type and receptor subtype (Bale and Vale 2004).
UCN1's dual high-affinity binding to both receptors means it integrates roles that are otherwise separated across the CRF family: CRF drives HPA axis activation and stress behavior via CRF1, while UCN2 and UCN3 mediate cardiovascular protection and appetite regulation via CRF2. UCN1 can do both, with its relative pharmacological output depending on the local receptor landscape.
Central nervous system actions: In the Edinger-Westphal nucleus and amygdala, UCN1 activates the HPA axis via CRF1, stimulating ACTH release and downstream cortisol production. Intracerebroventricular UCN1 potently suppresses food intake — one of the most effective central anorectic signals identified — and produces behavioral signs of stress and anxiety in rodents. Bale and Vale (2004) summarize evidence from CRF1 and CRF2 knockout mice establishing that the two receptor subtypes play opposing roles in stress sensitivity: CRF1 mediates anxiety and HPA activation, while CRF2 mediates anxiolysis and appetite suppression in regions such as the dorsal raphe nucleus.
Cardiovascular actions: UCN1 dilates systemic vasculature via CRF2 on vascular smooth muscle and endothelium. It increases myocardial contractility via CRF2 on cardiomyocytes and activates survival kinase pathways that protect cardiomyocytes from ischemia-reperfusion injury — effects described by Wright and colleagues (2009) as a "powerful array of hemodynamic, renal, and neurohumoral effects" in the setting of cardiac failure, consistent with the broad CRF2-mediated cardioprotective profile observed in preclinical models.
Gastrointestinal actions: UCN1 is present in the enteric nervous system and modulates gut motility. CRF1 activation stimulates colonic motility (contributing to stress-induced diarrhea), while CRF2 inhibits gastric emptying and upper GI transit. This bidirectional GI pharmacology via dual receptor engagement distinguishes UCN1 from the more receptor-selective UCN2 and UCN3.
Evidence
- Human: Wright and colleagues (Circulation: Heart Failure 2009) measured plasma UCN1 in patients with stable systolic heart failure and healthy age-matched controls, finding significantly elevated UCN1 in heart failure that correlated with NYHA functional class, NT-proBNP, and left ventricular ejection fraction. The authors propose that elevated UCN1 represents an adaptive counter-regulatory response — UCN1 acting via CRF2 to support myocardial function and oppose cardiomyocyte death. Human forearm blood flow studies have examined UCN1 hemodynamic pharmacology, confirming vasodilatory effects via CRF2 in vivo. Approximately 14 trials are registered on ClinicalTrials.gov for urocortin as of 2026, the majority examining forearm vascular pharmacology in healthy volunteers and heart failure patients.
- Animal: Intracerebroventricular urocortin suppressed food intake in rats (Vaughan et al. 1995). CRF family receptor knockout studies in mice established opposing roles for CRF1 and CRF2 in stress behavior and appetite regulation (Bale and Vale 2004). UCN2 modulates glucose utilization and insulin sensitivity in animal models, and UCN3 transgenic mice exhibit a metabolically favorable phenotype resisting obesity and hyperglycemia on a high-fat diet.
- In vitro: Synthetic urocortin displaced CRF from brain CRF receptors and stimulated ACTH release from cultured anterior pituitary cells in the original characterization (Vaughan et al. 1995). UCN1 effects on cardiomyocyte survival and ischemia-reperfusion injury protection have been characterized in isolated cell and perfused heart preparations.
Myths and misconceptions
- "Urocortin is just another name for CRF" — UCN1 and CRF are distinct peptides encoded by different genes (UCN vs. CRH), expressed in different brain regions (Edinger-Westphal nucleus vs. hypothalamic paraventricular nucleus), and with different receptor binding profiles: UCN1 binds both CRF1 and CRF2 with high affinity, while CRF preferentially binds CRF1. UCN1 stimulates ACTH release via CRF1 but is not the primary physiological driver of HPA axis activation — that role belongs to CRF released from the paraventricular nucleus (Bale and Vale 2004).
- "UCN1 is a cardiovascular drug" — UCN1 is not approved as a therapeutic. While preclinical and human vascular studies demonstrate UCN1's vasodilatory and cardiotropic properties via CRF2, clinical development has focused on UCN2 for heart failure indications. UCN1's simultaneous CRF1 activity drives HPA axis engagement and sympathetic activation, which complicates its cardiovascular pharmacological profile compared to the CRF2-selective UCN2.
- "UCN1, UCN2, and UCN3 all do the same thing" — The three urocortins differ fundamentally in receptor selectivity: UCN1 binds both CRF1 and CRF2 with high affinity; UCN2 and UCN3 are CRF2-selective. They differ in expression patterns and accordingly in their behavioral and metabolic effects (Bale and Vale 2004).
Common questions
Why is UCN1 elevated in heart failure — is it a cause or a consequence? The evidence from clinical studies (Wright and colleagues 2009) suggests UCN1 elevation in heart failure is primarily a consequence — a counter-regulatory response to myocardial stress. UCN1 expression in cardiomyocytes is induced by hypoxia and oxidative stress, stimuli present in the failing heart. The elevated UCN1 may represent an endogenous cardioprotective signal via CRF2, analogous to the adaptive natriuretic peptide response. Whether pharmacological augmentation of the UCN/CRF2 pathway would be beneficial in heart failure remains an open research question.
Is there a urocortin-based drug in development? No UCN1-based drug has entered late-phase clinical trials. UCN2, the CRF2-selective family member, has been evaluated in Phase I/II settings for acute decompensated heart failure and as an intravenous hemodynamic agent. UCN1's simultaneous CRF1 engagement — adding HPA axis activation and sympathetic drive to the cardiovascular pharmacology — makes it a less clean cardiovascular candidate than the CRF2-selective urocortins.
How does UCN1 differ from the other urocortins at the receptor level? UCN1 is the only CRF-family member with high affinity for both CRF1 and CRF2. Urocortin 2 and urocortin 3 bind CRF2 selectively, with negligible CRF1 affinity. CRF itself preferentially engages CRF1. UCN1 occupies a unique pharmacological position in the family: it can activate the full spectrum of CRF receptor biology from a single molecule (Bale and Vale 2004; Vaughan et al. 1995).
Related peptides
- ACTH (Corticotropin) — downstream effector of CRF/UCN1 signaling; secreted from anterior pituitary in response to CRF1 activation by urocortin and CRF; drives cortisol production from the adrenal cortex
- VIP (Vasoactive Intestinal Peptide) — class B GPCR neuropeptide in the same receptor superfamily; potent vasodilator expressed in overlapping peripheral tissues; used as a pharmacological comparator in vascular studies
- Secretin — class B GPCR gastrointestinal hormone; the secretin receptor (SCTR) is in the same receptor subfamily as CRHR1 and CRHR2, reflecting shared evolutionary ancestry of these neuropeptide systems
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
If a patient's body is already flooding their system with UCN1, does giving them more of it still help their heart?
If there is a ceiling on how much UCN1 can help, heart failure trials would need to pre-screen patients by their natural UCN1 levels to find who actually benefits. This could prevent expensive late-stage trial failures and focus treatment on the right patients.
Is the claim that UCN1 activates the GLP-1 receptor based on solid evidence, or could it be a mistaken annotation?
If the GLP-1R link is wrong, researchers could stop pursuing expensive drug combination strategies that will not work, and refocus on the stress-receptor pathways where UCN1 genuinely acts. Correcting the annotation saves time and clinical trial resources.
Does UCN1 protect heart cells directly, separate from its ability to widen blood vessels?
If these effects can be split apart, doctors could give patients a version of UCN1 that saves heart muscle during a heart attack without the dangerous blood pressure drop that currently limits its use. This could be especially important for patients who already have low blood pressure.
Could UCN1, a hormone made naturally in the gut, reduce intestinal inflammation in conditions like Crohn's disease?
If UCN1 can calm gut inflammation through a pathway that current drugs do not use, it might help the roughly one in three IBD patients who do not respond to existing treatments. A locally acting gut formulation could also avoid the whole-body hormonal side effects seen with systemic stress-hormone drugs.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.7888190150260925 | openfold3-mlx |
| ranking score | 0.8557884097099304 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.690 | global PDE — lower = better |
| disorder | 0.162 | fraction disordered |
| chain pair ipTM (A, B) | 0.789 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | aedd8f3eb814e392… |
| hardware | apple_m4_base_16gb |
| mlx version | 0.31.1 |
| python | 3.14.3 |
| random seed | 42 |
| msa strategy | colabfold |
| diffusion samples | 1 |
| runtime | 349s |
| predicted by | mlx@peptide |
| predicted at | 2026-04-22 |
python3 openfold3/run_openfold.py predict --query_json {query.json} --runner_yaml examples/example_runner_yamls/mlx_runner.yml --output_dir {output_dir} --num_diffusion_samples 1 ▸citationbibtex
@peptide{pep04476,
sequence = {DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV},
target = {crhr2},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}